l carnitine tartrate para que sirve BulkSupplements.com L-Carnitine L-Tartrate Capsules - Supplement, Carnitine 1000mg Capsules - L-Carnitine Tartrate, Gluten Free These statements have not been evaluated by the Food and Drug Administration (FDA) L-Carnitine Tartrate, 60 Capsules (500

Priority Applications (10) Applications Claiming Priority (2) Publications (1) Family ID=11455896 Family Applications (1) Country Status (17) Families Citing this family (1) Citations (1) Family Cites Families (6) 2001 2001-11-26 IT IT2001RM000695A patent/ITRM20010695A1/en unknown 2002 2002-11-26 PL PL371012A patent/PL209317B1/en unknown 2002-11-26 PT PT02793337T patent/PT1448184E/en unknown 2002-11-26 KR KR1020047007881A patent/KR100923139B1/en not_active Expired - Fee Related 2002-11-26 ES ES02793337T patent/ES2261772T3/en not_active Expired - Lifetime 2002-11-26 DK DK02793337T patent/DK1448184T3/en active 2002-11-26 WO PCT/IT2002/000745 patent/WO2003045373A1/en not_active Ceased 2002-11-26 DE DE60210804T patent/DE60210804T2/en not_active Expired - Lifetime 2002-11-26 CA CA2466135A patent/CA2466135C/en not_active Expired - Fee Related 2002-11-26 AU AU2002358991A patent/AU2002358991A1/en not_active Abandoned 2002-11-26 MX MXPA04004900A patent/MXPA04004900A/en active IP Right Grant 2002-11-26 AT AT02793337T patent/ATE323481T1/en active 2002-11-26 EP EP02793337A patent/EP1448184B1/en not_active Expired - Lifetime 2002-11-26 JP JP2003546875A patent/JP4370168B2/en not_active Expired - Fee Related 2002-11-26 HU HU0402118A patent/HUP0402118A3/en unknown 2002-11-26 US US10/496,659 patent/US20050038044A1/en not_active Abandoned 2006 2006-05-30 CY CY20061100685T patent/CY1105347T1/en unknown

Reference Galon, Maciel, Agostinetto, Conceno and Moraes2011

References Beliaev A, Learmonth DA, Soares-da-Silva P

Growth hormone is thought to interact with growth hormone receptors on different cells and stimulate IGF-1 synthesis, which in this experiment appeared to be increased by 2728% following the Sermorelin experimentation

KD can alleviate oxidative stress in the kidneys by modulating metabolic pathways and epigenetic mechanisms, thereby potentially providing therapeutic benefits for DKD